Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: 1 mg as a single dose, given in the morning or early evening, then 1 mg after 6-8 hr if necessary.
Elderly: 0.5 mg daily.

Emergency cases of oedema
Adult: 0.5-1 mg via IM or slow IV inj over 1-2 min, a 2nd or 3rd dose may be given at 2-3 hr intervals if response is inadequate. Max: 10 mg daily.
Cách dùng
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Chống chỉ định
Anuria, hepatic coma, severe electrolyte depletion. Concurrent use w/ lithium.
Thận trọng
Patient w/ sulfonamide allergy, prostatic hypertrophy. Hepatic (i.e. cirrhosis and ascites) and renal impairment. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Abdominal pain, vomiting, dyspepsia, diarrhoea, stomach and muscle cramps, arthralgia, dizziness, fatigue, hypotension, headache, nausea, fluid and electrolyte depletion, encephalopathy (in patients w/ pre-existing liver disease), dehydration, hyperuricaemia, increased BUN and serum creatinine, hyperglycaemia, abnormal serum hepatic enzymes, skin rash, pruritus, urticaria, thrombocytopenia, gynaecomastia and painful breasts. Rarely, reversible hearing disturbance.
IV/Parenteral/PO: C
Chỉ số theo dõi
Monitor BP, serum electrolytes, renal function, fluid status.
Quá liều
Symptoms: Profound water loss, volume and electrolyte depletion (manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps), dehydration, reduction of blood volume and circulatory collapse w/ possible thrombosis and embolism. Management: Supportive and symptomatic treatment, including fluid and electrolyte replacement. Perform gastric lavage or emesis.
Tương tác
Reduced diuretic and natriuretic effect w/ probenecid. May potentiate the effects of antihypertensive agents. Decreased effect when used w/ indometacin. May increase risk of digitalis toxicity. Increased risk of ototocixity when used w/ aminoglycosides or other ototoxic drugs (e.g. cisplatin). Increased risk of nephrotoxicity when used w/ nephrotoxic agents.
Potentially Fatal: May increase risk of lithium toxicity.
Tác dụng
Mechanism of Action: Bumetanide inhibits Na and Cl reabsorption in the loop of Henle and proximal renal tubule, interfering w/ the Cl-binding cotransport system, thus inducing excretion of water and electrolytes.
Onset: 0.5-1hr (oral, IM); 2-3 min (IV).
Duration: 4-6 hr (oral); 2-3 hr (IV).
Absorption: Almost completely and rapidly absorbed from the GI tract; completely absorbed (IM). Bioavailability: Approx 80-95%. Time to peak plasma concentration: 0.5-2 hr (oral).
Distribution: Volume of distribution: 9-25 L. Plasma protein binding: 94-96%.
Metabolism: Partially metabolised in the liver via oxidation of the N-butyl side chain to form alcohol metabolites.
Excretion: Via urine (approx 75-80%, w/ 50% as unchanged drug); faeces (approx 10%) Elimination half-life: 1-1.5 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Bumetanide, CID=2471, https://pubchem.ncbi.nlm.nih.gov/compound/Bumetanide (accessed on Jan. 22, 2020)

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Thuốc lợi tiểu
Phân loại ATC
C03CA02 - bumetanide ; Belongs to the class of high-ceiling sulfonamide diuretics.
Tài liệu tham khảo
Anon. Bumetanide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/08/2016.

Buckingham R (ed). Bumetanide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/08/2016.

Bumetanide Inj, Solution (Hospira, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/08/2016.

Bumetanide Tablet (Edenbridge Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/08/2016.

Joint Formulary Committee. Bumetanide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Bumetanide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/08/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bumetanide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in